Company Overview
Snapshot
Founded in September 2022 by Gil Senesh, BeCapio operates with 1–10 employees. The company has secured funding across one disclosed round from two investors, including The Trendlines Group. BeCapio is currently in the R&D product stage, developing non-invasive therapeutic solutions.
Business overview
BeCapio is a Health Tech & Life Sciences company focused on developing solutions for individuals dealing with Fecal Incontinence Disorder. The company's core offering is a discrete, non-invasive, multi-modal therapy designed to help patients regain control and maintain everyday activities. BeCapio operates within the Digital Healthcare and Digital Therapeutics sectors, targeting patients in the broader Healthcare & Life Sciences market.
Log in to access full profile ›Company Intelligence Q&A
- When was BeCapio founded?
- BeCapio was founded in September 2022 by Gil Senesh.
- What is BeCapio's primary focus?
- BeCapio focuses on providing a discrete, non-invasive, multi-modal therapy to help people dealing with Fecal Incontinence Disorder regain control and maintain everyday activities.
- Which investors participated in BeCapio's funding round?
- In November 2022, BeCapio received funding from The Trendlines Group and Israel Innovation Authority.
- What is the employee count for BeCapio?
- BeCapio currently operates with 1–10 employees.
- What stage is BeCapio's product development in?
- BeCapio's product is currently in the R&D stage, working towards developing a non-invasive, multi-modal therapy for fecal incontinence.